Targeted breast cancer drug – olaparib – given green light by EU 16 Apr 2019 European Medicines Agency approves olaparib for women with BRCA-mutant breast cancer – 15 months after licensing in the US. Find out more Show/Hide
ICR responds to NICE decision on olaparib for women with advanced ovarian cancer 09 Nov 2018 NICE has announced today, its decision not to recommend olaparib for women with advanced ovarian cancer who had previously responded to platinum chemotherapy for six months or longer. Find out more Show/Hide
Scientists identify cause of resistance to breakthrough breast and ovarian cancer drug 10 May 2018 The study findings could help predict which patients will develop resistance to PARP inhibitors and allow doctors to alter treatment at the earliest possible opportunity. Find out more Show/Hide
The ICR responds to the FDA approval of olaparib for women with BRCA-mutant advanced breast cancer 12 Jan 2018